Q3 2026 lobbying ▼ Spend −75% Ended · Ferox Filed Oct 19
Q3 spend$20KQ2 $80K
QoQ−75.0%vs Q2 2026
YoY−75.0%vs Q3 2025
AgenciesCongress onlyHouse, Senate
HCRHealth Issues
Lobbied on Rare disease pharmaceuticals, and general FDA reforms rare disease
Bills No bills named in Q3 2026 filings
No member trades in 90 days Stock page ›